Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20149663 | 0.87 | DNM1 (0.60) | MEN1KMT2A | |
| SCHEMBL20138868 | 0.86 | LSS (0.44) | TRPV1 | |
| SCHEMBL20149580 | 0.84 | DNM1 (0.54) | CNR1ALDH1A1TRPV1MAPT | |
| SCHEMBL20149581 | 0.84 | DNM1 (0.48) | TRPV1 | |
| SCHEMBL22046686 | 0.81 | ALDH1A1 (0.61) | CNR1ALDH1A1HPGDTDP1 | |
| SCHEMBL28005061 | 0.81 | HRH3 (0.54) | MEN1KMT2AMAPTBLMTDP1 | |
| SCHEMBL23499202 | 0.81 | DNM1 (0.76) | MEN1KMT2ACNR1ALDH1A1HPGD | |
| SCHEMBL7031534 | 0.81 | DNM1 (0.76) | MEN1KMT2ACNR1ALDH1A1HPGD | |
| SCHEMBL23499203 | 0.81 | DNM1 (0.76) | MEN1KMT2ACNR1ALDH1A1HPGD | |
| SCHEMBL30540103 | 0.81 | DNM1 (0.76) | MEN1KMT2ACNR1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250162978-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | UNIV RAMOT (IL) | 2025-05-22 | — | — | US | claimed |
| US-11851389-B2 | Cationic lipids for nucleic acid delivery and preparation thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-12-26 | — | — | US | claimed |
| US-20190292130-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-09-26 | — | — | US | claimed |
| EP-3538515-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | Ramot at Tel-Aviv University Ltd. (IL) | 2019-09-18 | — | — | EP | claimed |
| WO-2018087753-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) | 2018-05-17 | — | — | WO | claimed |
| EP-3538515-B1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | UNIV RAMOT (IL) | 2022-07-20 | — | — | EP | disclosed |
| US-20220162552-A1 | Nonviral Modification of T Cell Gene Expression | Precision Nanosystems Inc. (CA) | 2022-05-26 | — | — | US | disclosed |
| EP-3956459-A1 | NONVIRAL MODIFICATION OF T CELL GENE EXPRESSION | Precision Nanosystems Inc (CA) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020210901-A1 | NONVIRAL MODIFICATION OF T CELL GENE EXPRESSION | Precision Nanosystems Inc. (CA) | 2020-10-22 | — | — | WO | disclosed |
| US-20190292130-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-09-26 | — | — | US | disclosed |
| WO-2018087753-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851389-B2 | Cationic lipids for nucleic acid delivery and preparation thereof | NPC1L1, NPC1, CETP | MEN1 1830/4885KMT2A 1852/4885CNR1 3460/4885 |
| US-20250162978-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | NPC1L1, NPC1, CETP | MEN1 1830/4885KMT2A 1852/4885CNR1 3460/4885 |
| US-20190292130-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | NPC1L1, NPC1, CETP | MEN1 1830/4885KMT2A 1852/4885CNR1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.